APIs for research and impurities

Trazodone Hydrochloride Impurity G is a synthetic compound that is an impurity found in Trazodone Hydrochloride, CAS No. 77893-17-6. This compound has the following physical properties: MW = 284.27, mp = 227-229°C, [α] D = -33.5° (c 1.0 in water), and UV max (λ max ) = 228 nm. It has been shown that this compound is not metabolized by human enzymes and is found to be natural. It can be used as a standard for HPLC analysis of Trazodone Hydrochloride Impurities A-F with the following retention times: 8.7 min for Impurity A, 9.2 min for Impurity B, 9.9 min for Impurity C, 10.4 min for Impurity D, 11.1 min for Impurity E, and 12.3 min for Impurity F.BR>BR

Cetirizine is a drug product that is metabolized to cetirizine propanediol ester. This impurity has been identified in the drug and is not expected to cause any adverse effects in humans. Cetirizine propanediol ester can be synthesized and purified through high-purity, analytical, and natural methods. The pharmacopoeia defines cetirizine propanediol ester as a metabolite of cetirizine. It can also be used as an impurity standard for HPLC analysis.

Dicyclopropylamine is a molecule that has been clinically developed as a drug. It is an inhibitor of the enzyme tyrosinase, which is involved in the production of melanin, and has been shown to have anti-cancer properties. Dicyclopropylamine hydrochloride has been shown to be effective against aliphatic hydrocarbons such as hexane and cyclohexane, as well as aromatic compounds such as benzene and toluene. This drug can also bind to coordination complexes with high kinetic energy, which may be useful for tumor treatment. Dicyclopropylamine hydrochloride can be used for the clinical treatment of human epidermoid carcinoma.

Please enquire for more information about 4-Desmethyl 5-methyl vortioxetine hydrochloride including the price, delivery time and more detailed product information at the technical inquiry form on this page

CPI 0610 is a medicinal compound that acts as a potent inhibitor of protein phosphorylation. It has been shown to inhibit the cell cycle and promote apoptosis in Chinese hamster ovary cells. CPI 0610 is an effective inhibitor of kinase activity in cancer cells, leading to decreased tumor growth and increased survival rates. In preclinical studies, CPI 0610 has demonstrated efficacy against a wide range of cancers, including breast, prostate, and lung cancer. This inhibitor has also been shown to be effective in human cancer cell lines, making it a promising candidate for future cancer therapies.

1-Phenyl-1,2,3,4-tetrahydro-isoquinoline is a synthetic compound which has been used as a lead compound for the development of drugs with dopamine β-hydroxylase inhibitory activity. In vitro studies have shown that 1-phenyl-1,2,3,4-tetrahydro-isoquinoline inhibits human serum dopamine β-hydroxylase and can be used to study the possible role of this enzyme in Parkinson's disease. This drug is racemized in the body and has been found to be effective against Parkinson's disease in rats. It is also an enantiomer that has industrial applications for the production of polyurethane foam insulation coatings.

Fonofos is a potent inhibitor that has been shown to induce apoptosis in Chinese hamster ovary cells. It is also known to inhibit chitin kinase, a protein that plays an important role in the biosynthesis of chitin, which is essential for the formation of cell walls in fungi and insects. Fonofos has medicinal properties and has been studied as a potential anticancer agent due to its ability to inhibit tumor growth. In vitro studies have shown that Fonofos can inhibit the growth of human cancer cells by inhibiting heparin-binding proteins. Additionally, it has been found to have inhibitory effects on several other enzymes involved in cancer development and progression. Although not approved for use in humans, Fonofos may hold promise as a therapeutic agent for the treatment of certain cancers.

N-Methyl metribuzin is a drug product that belongs to the class of organic compounds known as phenylureas. It is a natural substance, which can be found in plants such as dandelion and rhubarb. Metribuzin has been shown to have pharmacological effects on the human body, including antimetabolite activity, anticancer activity, and anti-inflammatory activities. Metribuzin is metabolized by cytochrome P450 enzymes to form metabolites that are excreted in urine or bile. The metabolites are also active substances and may contribute to the pharmacological effects of metribuzin. Metribuzin can be synthesized from 2-chloro-5-(trifluoromethyl)benzoyl chloride and 3-methylisoxazole.
Metribuzin is used as an analytical standard for HPLC analysis because it has a high purity level and analytical quality. It is also used in

N-Desmethyl trimeprazine is a synthetic compound, which is an impurity of the drug product. It is not active and does not possess any biological activity. It is a metabolite of the parent drug, Trimeprazine. N-Desmethyl trimeprazine has been studied for its pharmacological properties and metabolism in the body, but no conclusive results have been found. The chemical structure and purity of N-Desmethyl trimeprazine are not listed in the USP or BP. This compound can be custom synthesized on request.

4-(Phthalazin-1-yloxy)aniline is an analog of cyclin-dependent kinase (CDK) inhibitors that has shown promising anticancer activity. It inhibits the activity of CDKs, which are enzymes involved in regulating cell division and proliferation. This compound has been tested on Chinese hamster ovary cells and has demonstrated potent antiproliferative activity against various cancer cell lines. 4-(Phthalazin-1-yloxy)aniline induces apoptosis in tumor cells, leading to their death. This compound may be a potential candidate for the development of novel anticancer drugs that target CDKs and promote tumor cell death. Additionally, this compound can be detected in urine samples, making it a useful biomarker for cancer diagnosis and monitoring.

Pirtenidine is a potent and selective kinase inhibitor that has been shown to inhibit the activity of cyclin-dependent kinases. It has demonstrated promising results in preclinical studies as an anticancer agent, inducing apoptosis in cancer cells. Pirtenidine is an analog of protein kinase inhibitors, which have been used to treat various types of tumors. It has been found to be effective against human cancer cell lines and has shown significant tumor growth inhibition in animal models. Pirtenidine has also been reported to be a potent urine inhibitor of Chinese hamster ovary cells, making it a promising candidate for the treatment of urinary tract cancers.

Xanthoxin is a medicinal compound with potent anticancer properties. It has been shown to induce apoptosis, or programmed cell death, in cancer cells. Xanthoxin has been tested in various cancer cell lines, including Chinese and human cells, and has demonstrated strong inhibitory effects on the tumor cycle. This compound works by inhibiting kinases and other proteins involved in cancer cell growth and proliferation. Xanthoxin is also known to be an inhibitor of certain urinary proteins that are associated with cancer progression. Overall, Xanthoxin shows great potential as a natural product for the development of novel anticancer therapies.

Please enquire for more information about (E/Z)-It-603 including the price, delivery time and more detailed product information at the technical inquiry form on this page

Please enquire for more information about Acrolein-d4 including the price, delivery time and more detailed product information at the technical inquiry form on this page

Simvastatin acid is the active form of simvastatin, a drug used to lower blood cholesterol levels. Simvastatin acid inhibits HMG-CoA reductase, the enzyme that converts HMG-CoA to mevalonate. This conversion is a rate-limiting step in the synthesis of cholesterol and other lipids. Simvastatin acid binds to polymerase chain and drug transporter proteins, which leads to cell lysis. The concentration–time curve for simvastatin acid is linear and the half-life is approximately 12 hours. When simvastatin acid is administered with drugs that are potent inducers of CYP3A4 or UGT1A1 enzymes, there may be an increased risk for drug interactions. Simvastatin acid has shown no significant human pharmacokinetic interactions with food or grapefruit juice at doses up to 200 mg/day. There are limited data on the pharmacokinetics of simvastatin